Our website uses cookies

Cookies are small text files held on your computer. They allow us to give you the best browsing experience possible and mean we can understand how you use our site. Some cookies have already been set. You can delete and block cookies but parts of our site won't work without them. By using our website you accept our use of cookies. Find out more about cookies.

Click here to dismiss this banner

YOU MIGHT BE INTERESTED IN

  1. Biosimilars And Follow-On Biologics: World Market 2013-2023

    Biosimilars And Follow-On Biologics: World Market 2013-2023

    Biosimilar drugs - discover trends and areas with highest revenue potential. Do you want to find the sales potential of biosimilars? Visiongain's updated report gives you revenue predictions for those biological drugs from 2013, helping you stay ahead. There you find financial data, R&D trends, opportunities and discussions of prospects. In that work you see forecasted sales to 2023 at overall world market, submarket, molecule and national level. You also assess emerging trends, technologies and expected products.

    ...more details
  2. Next-Generation Antibody Therapeutics Market 2013-2023

    Next-Generation Antibody Therapeutics Market 2013-2023

    Where are therapeutic antibodies heading? Visiongain's updated report gives you revenue predictions to 2023. There you see sales data, R&D trends, outlooks and opportunities. You find the potential of monoclonal antibodies (mAbs) and other immunotechnology. See forecasted sales at overall world market and submarket level. Also assess emerging trends and expected products. Many opportunities remain - you discover the areas to prosper.

    ...more details
  3. Macular Degeneration (AMD) and Other Retinal Diseases: World Drug Market 2014-2024

    Macular Degeneration (AMD) and Other Retinal Diseases: World Drug Market 2014-2024

    What's the future for treating disorders of the retina? Visiongain's updated report forecasts those pharma revenues. There you find outlooks for sales growth in that industry. You also explore trends, technologies, therapies, and opportunities. That analysis gives you predictions of revenues to 2024 at overall world market, submarket, product, and national level. Avoid falling behind in data, then, missing business or losing influence. So find what's happening for those ocular medicines. Discover how you can gain.

    ...more details
  4. Diabetes Treatments: World Drug Market 2013-2023

    Diabetes Treatments: World Drug Market 2013-2023

    Where's the diabetic treatments market heading? How are those products performing? Visiongain's updated report gives you forecasted revenues there to 2023 and also explains R&D trends, outlooks and commercial opportunities. Our study lets you assess sales data and predictions for the world antidiabetic medicines market, therapeutic submarkets, products and national markets. Those analyses show you that pharmaceutical field's most promising and lucrative segments.

    ...more details
  5. Parkinson's Disease: World Drug Market 2013-2023

    Parkinson's Disease: World Drug Market 2013-2023

    Where are treatments for Parkinson's disease heading - technological and commercial outlooks? Visiongain's updated report gives you forecasted revenues to 2023 and shows you R&D trends, opportunities and industry prospects. Emerging technologies hold promise. Our new study investigates developments, also letting you assess projected sales data at overall world market, submarket and national level. There you investigate the most promising areas in that industry and market segment for neurodegenerative disorders.

    ...more details
  6. Pharma Wholesale and Distribution Market: World Outlook 2013-2023

    Pharma Wholesale and Distribution Market: World Outlook 2013-2023

    Where's the drug wholesaling and distribution market heading? Visiongain's updated report predicts revenues there from 2013 to 2023. It also explains trends in business and technology, prospects, and opportunities to help your work. In that study you gain sales forecasts at overall world market, submarket, company, and national level.

    ...more details
  7. Single-Use Bioreactors for Pharma: World Market 2013-2023

    Single-Use Bioreactors for Pharma: World Market 2013-2023

    Where's the single-use bioreactors market heading? How are these products performing? Visiongain's updated report gives you forecasted revenues there to 2023 and also explains R&D trends, outlooks and commercial opportunities. Our study lets you assess sales data and predictions for the world single-use bioreactors market, submarkets, important products and national markets. Those analyses show you that pharmaceutical field's most promising and lucrative segments.

    ...more details
  8. Leading Anti-Cancer Drugs and Associated Market 2013-2023

    Leading Anti-Cancer Drugs and Associated Market 2013-2023

    Do you want to assess the future of cancer medicines? Visiongain's updated report gives you revenue predictions there from 2013, helping you stay ahead. You find financial data, R&D trends, opportunities, and outlooks. In that work you see forecasted sales to 2023 at overall world market, submarket, product, and national level. You also assess emerging trends, technologies, and expected drugs.

    ...more details
  9. Biosimilar Monoclonal Antibodies: World Market Prospects 2013-2023

    Biosimilar Monoclonal Antibodies: World Market Prospects 2013-2023

    What does the future hold for biosimilar therapeutic antibodies? Visiongain's new report predicts revenues to 2023. There you find the best places for sales growth, also understanding trends and opportunities. In that study you get revenue forecasts at overall world market, submarket, product, and national level. See what's happening for those technologies, finding how you can gain.

    ...more details
  10. Orphan Drugs for CNS Diseases: R&D and Market 2014-2024

    Orphan Drugs for CNS Diseases: R&D and Market 2014-2024

    Uncommon nerve disorders - new study explains technological and commercial prospects. What's the future of medicines for rare central nervous system (CNS) disorders? Visiongain's new report gives you predictions for those therapies. Stay ahead. There you explore sales results, technologies, R&D trends, opportunities, and revenue forecasts.

    ...more details

PHARMA REPORT

rss_Pharma.jpg...see all
World Biological Drugs Market 2013-2023

World Biological Drugs Market 2013-2023

  • Publication date: 13/05/2013
  • Number of Pages: 358
  1. Report Details
  2. Table of Contents
  3. Companies Listed

Report Details

Biologics - discover and assess products with highest revenue potential

Do you want to find sales potentials of biological drugs? Visiongain's updated report gives you revenue predictions for biologics from 2013, helping you stay ahead. There you find financial data, R&D trends, opportunities, and discussions of prospects.

In that work you see forecasted sales to 2023 at overall world market, submarket, product, and national level. You also assess emerging trends, technologies, and expected products.

You see what shapes the biologics industry, discovering its commercial potential

Discover, then, what the future holds for biologics (biologicals). Read on to see features of the biopharma industry and discover what its future market could be worth.

Forecasts and other analyses show you trends and best prospects

Besides revenue forecasting to 2023, you find historical data, growth rates, and market shares. There you assess quantitative and qualitative analysis, news, outlooks, and developments (R&D). You also gain 174 tables, 129 charts, and four research interviews.

Many opportunities remain for biological drugs, because of their increasing use. Our study shows you the most lucrative parts of that market, helping you stay ahead. Now see how you can benefit your research, analyses and decisions.

Finding data you need has just got easier. The following sections show how you benefit from our new analysis.

Discover sales predictions for the world biologics market and its submarkets

Along with revenue prediction for the overall world market for biological drugs, our work shows forecasts from 2013 to 2023 for individual submarkets:
• Protein therapeutics - with sub forecasts for insulins, other recombinant hormones, plasma and recombinant coagulating factors, interferons, and other agents
• Monoclonal antibodies (mAbs) - with sub forecasts for autoimmune, anticancer, and other agents
• Fusion proteins
• Cellular and regenerative medicines - with sub forecasts for tissue-engineered products, cellular therapies, and gene therapy.

Our report shows you revenue potentials of biopharmaceuticals, helping you find opportunities to develop your business.

Also our investigation discusses what stimulates and restrains sales of biotechnological medicines. There you explore that industry, seeing what products can achieve the most success.

Discover sales forecasts for prominent brands

Our new study forecasts revenues of 13 leading products, including these:
• Lantus
• Epogen
• Avonex
• NovoRapid
• Humira
• Remicade
• Rituxan
• Herceptin
• Avastin.

There you discover how high sales can go, to 2023, with individual forecasts. You see what's happening, understanding trends, competition, challenges, and opportunities.

The report also divides its overall world forecast into those for geographical regions.

Leading national markets - where will highest revenues and growth occur?

Developments worldwide will influence the biologicals market, especially rising demand in developed and developing countries. Find progress and opportunities there.

Our analyses show you individual revenue forecasts to 2023 for eleven national markets:
• United States (US)
• Japan
• EU leaders - Germany, France, the UK, Italy, and Spain (EU5)
• BRIC countries - Brazil, Russia, India, and China.

There you discover prospects and potential sales. You assess the biological drug industry's future - hear about developments and find their significance. In particular, drug launches will change medical prescribing from 2013 to 2023.

Research and development - you see trends and possibilities for new therapies

What about R&D - the pipeline for new drugs? You see trends for these agents:
• Insulins and other recombinant hormones
• Plasma and recombinant coagulating factors
• Interferons and other protein therapeutics
• Rheumatoid arthritis (RA), other autoimmune, and asthma mAbs
• Multiple sclerosis (MS), lupus, and psoriasis mAbs.

Our study also discusses these biotechnologies in development:
• Cancer (oncology) and cardiovascular mAbs
• Alzheimer's disease, ophthalmic, and anti-infective mAbs
• Fusion proteins
• Tissue-engineered products
• Cellular therapies
• Gene therapy.

R&D for biological drugs holds strength, variety, and promise. You assess innovations, hearing about developments and finding their significance. Discover progress.

In particular, mAbs and fusion proteins hold potential, with more than 25 late-stage candidates and several emerging technologies.

Anyhow, for large companies and specialty pharma firms, there exist many therapeutic and commercial opportunities. Our study explains. See, then, what the future holds.

Leading companies and 2017 market value

From 2013, product launches there hold great potential for investment, uptake, and revenues. Our study predicts the world market for biologics will reach $178.4bn in 2017, with further growth to 2023. See how high revenues can go.

There you assess what biopharma technologies, products types, and companies hold most potential. Our analyses cover these and many other developers and producers:
• Roche
• Amgen
• Novo Nordisk
• AbbVie
• Johnson & Johnson.

In our report you find 284 organisations mentioned. Also, you read four interviews with other authorities. Find out what shapes the industry.

R&D for biologicals is strong, and from 2013 there will arise many opportunities. There are prospects for new drugs and overall sales growth. Our work shows the possibilities, helping you stay ahead.

Nine ways World Biological Drugs Market 2013-2023 helps you

In particular, then, our investigation gives you the following knowledge:
• Revenue to 2023 for the world biologics market - discover that industry's overall sales prospects
• Revenues to 2023 for 15 world-level submarkets - investigate the potential of its components, finding the most promising places for investments and revenues
• Prospects to 2023 for 13 leading products - see revenue forecasts for top brands
• Forecasts to 2023 for 11 leading national markets in the Americas, Europe, and Asia - discover the best regions and countries for revenues and potential growth
• Activities of leading companies - hear about participants' actions, capabilities, results, and outlooks
• Charting and discussions of R&D - explore progress in the biological drugs industry, finding technological, medical, and commercial possibilities
• Interviews with other experts on biologicals - discover what authorities in that field think, say, and do, helping you stay ahead
• Competition and opportunities - investigate what shapes that market's future, including ways to develop business
• Analysis of what stimulates and restrains the biopharma market - assess challenges and strengths, helping you compete and gain advantages.

You gain information found nowhere else

That work gives independent analysis. There you receive business intelligence found only in our report, seeing where prospects are most rewarding.

With our new study you are less likely to fall behind in knowledge or miss opportunity. See there how you could benefit your research, analyses, and decisions, also saving time.

Discover potential now in the biologics market and find what you can gain.

For biologics, see commercial prospects from 2013 by ordering now

Our investigation is for everyone analysing the industry and market for biological drugs. There you find data, trends, opportunities, and predictions. Please order that report now.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

To view free sample pages of this report please click here

Table of Contents

1. Executive Summary
1.1 World Biological Drugs Market Review
1.2 Summary of Report Contents
1.3 Research and Analysis Methods

2. Biological Drugs Market: Clinical and Commercial Overview, 2013-2023
2.1 Biologics Market Projections for 2013-2023
2.2 The Importance of Biological Drugs to the Global Pharmaceutical Market
2.2.1 Defining 'Biological'
2.2.2 Biological Drugs Constituted 15% of the Global Pharmaceutical Market in 2012
2.2.2.1 The Leading Biological Products and How they Rank Overall
2.2.2.2 Why are Biologics the Most Lucrative Pharmaceutical Products in the Global Market Overall?
2.2.3 The Biosimilars Revolution: Coming Soon?
2.2.3.1 Biosimilars Represented Just Over 1% of the Biologics Market in 2012
2.2.3.2 An Important Decade for Biosimilars
2.2.4 Autoimmune Diseases, Cancer and Diabetes Treatments Make Up 73% of the Biologics Market
2.2.4.1 Other Therapeutic Areas within the Biologics Market
2.2.4.2 How the Biologics Market's Therapeutic Focus Differs from the Broader Pharmaceutical Market
2.2.5 Roche Still Leads the Biologics Market
2.3 Overview of the Four Submarkets, 2013-2023
2.3.1 Superior Pipeline Will Drive Increased Market Share for MAbs Submarket
2.4 Protein Therapeutics Submarket: Scientific and Historical Background
2.4.1 Proteins Have Been Used Medicinally Since the 19th Century
2.4.2 Recombinant DNA Technology
2.4.3 Biotechs and Biotechnology
2.4.4 Insulin: The First Protein Therapeutic
2.4.5 Approval of Recombinant Hormones
2.4.6 Discovery of Plasma and Clotting Proteins
2.4.7 Interferons Approved in 1990s
2.4.8 Other Protein Therapeutics
2.5 MAbs Submarket: Scientific and Historical Background
2.5.1 Natural Antibodies: Key to the Immune System
2.5.2 From Serum Therapy to Monoclonal Antibodies (MAbs)
2.5.3 Humanising the MAb
2.5.4 MAbs for Autoimmune Indications
2.5.5 MAbs for Cancer Indications
2.5.6 MAbs for Other Therapeutic Area Indications
2.5.7 MAbs for All? The Technology Comes Off Patent
2.5.8 Next-Generation Technologies
2.6 Fusion Proteins Submarket: Scientific and Historical Background
2.6.1 Differentiating Fusion Proteins
2.7 Cellular and Regenerative Medicines Submarket: Scientific and Historical Background
2.7.1 Tissue Engineering
2.7.2 Cellular Therapies
2.7.3 Gene Therapy
2.8 Marginal Cases
2.8.1 The Vaccines Market

3. Protein Therapeutics Submarket, 2013-2023
3.1 Protein Therapeutics Submarket Projections for 2013-2023
3.2 Protein Therapeutics Submarket: Breakdown by Segment, 2013-2023
3.2.1 Insulins Segment: Set to Grow Rapidly to 2023
3.2.1.1 Novo Nordisk, Sanofi and Eli Lilly Dominate the Insulins Segment
3.2.1.2 Duration of Action the Major Differentiator for Insulins
3.2.1.3 Tresiba: A Game-Changer for the Segment?
3.2.1.4 Pegylated Insulins, Ultra-Concentrated Insulins, and Insulin Tablets: Insulin Pipeline for the Big Three
3.2.1.5 Biosimilars and Other Insulins in Development
3.2.1.6 Diabetes Prevalence the Major Driver for Insulins
3.2.1.7 Market Forecast for Insulins Segment, 2013-2023
3.2.2 Other Recombinant Hormones: Set for Biosimilar Competition
3.2.2.1 Revenues for Erythropoietins Continue to Fall in 2012
3.2.2.2 Biosimilars, Safety Concerns and Other Restraints for Erythropoietins
3.2.2.3 G-CSF: How Long Can Amgen and Kyowa Continue to Dominate?
3.2.2.4 Biosimilar Filgrastim and Pegfilgrastim to Reach All the Major Regional Markets
3.2.2.5 Somatropin: Another Well-Established Recombinant Hormone
3.2.2.6 Biosimilar and Safety Challenges to Growth Hormones
3.2.2.7 Pipeline for Other Recombinant Hormones
3.2.2.8 Drivers and Restraints for Other Recombinant Hormones
3.2.2.9 Market Forecast for Other Recombinant Hormones Segment, 2013-2023
3.2.3 Plasma and Recombinant Coagulating Factors: A Growth Opportunity
3.2.3.1 Types of Recombinant Factor
3.2.3.2 Key Clotting Factor Deficiency Diseases
3.2.3.3 Six Companies Dominate the Segment
3.2.3.4 Other Companies Targeting this Segment: Biogen Idec Leads the Pack
3.2.3.5 Extended Duration of Action to be a Differentiator
3.2.3.6 Limited Opportunities for Biosimilar Challenges
3.2.3.7 Other Pipeline Developments
3.2.3.8 Drivers and Restraints for Plasma and Recombinant Coagulating Factors, 2013
3.2.3.9 Market Forecast for Plasma and Recombinant Coagulating Factors Segment, 2013-2023
3.2.4 Interferons: Two Decades as Key Antiviral and MS Therapeutics
3.2.4.1 Leading Interferon Brands in 2012
3.2.4.2 Interferons Remain Part of Hepatitis Standard of Care Despite Severe Limitations
3.2.4.3 How Will Interferons Compete Against the Pipeline Protease and Polymerase Inhibitors?
3.2.4.4 Aubagio, Tecfidera and Lemtrada to Reduce Interferons' Hold on the MS Therapeutic Area
3.2.4.5 Biosimilar First-Generation Interferons Widely Available in Emerging Markets
3.2.4.6 Can the Pipeline Rejuvenate the Interferons Segment?
3.2.4.7 Drivers and Restraints for the Interferons Segment, 2013
3.2.4.8 Market Forecast for Interferons Segment, 2013-2023
3.2.5 Other Protein Therapeutics: Enzyme Replacement A Key Area
3.2.5.1 Pipeline for Other Protein Therapeutics
3.2.5.2 Market Forecast for Other Protein Therapeutics Segment, 2013-2023
3.3 Leading Products in the Protein Therapeutics Submarket, 2013-2023
3.3.1 Changing Market Shares, 2013-2023
3.3.2 Lantus (Sanofi), 2013-2023
3.3.2.1 Tresiba's Cardiovascular Concerns Mean Lantus Will Stay In Front
3.3.2.2 Market Forecast for Lantus, 2013-2023
3.3.3 Neulasta/Neupogen (Amgen), 2013-2023
3.3.3.1 Biosimilars the Main Concern for Amgen
3.3.3.2 Market Forecast for Neulasta/Neupogen, 2013-2023
3.3.4 Epogen (Amgen), 2013-2023
3.3.4.1 Amgen's Defence of Epogen's Market Share
3.3.4.2 Market Forecast for Epogen, 2013-2023
3.3.5 Avonex (Biogen Idec), 2013-2023
3.3.5.1 How Will Avonex Fare in the Changing MS Therapeutic Area?
3.3.5.2 Market Forecast for Avonex, 2013-2023
3.3.6 NovoRapid (Novo Nordisk), 2013-2023
3.3.6.1 Competition in the Short-Acting Insulin Analogues Market
3.3.6.2 Market Forecast for NovoRapid, 2013-2023
3.3.7 Other Products, 2013-2023
3.3.7.1 Major Future Approvals in this Submarket
3.3.7.2 Market Forecast for Other Products, 2013-2023
3.4 Leading Products in Development in the Protein Therapeutics Submarket, 2013
3.4.1 Recombinant Factor XIII (Novo Nordisk)
3.4.2 NN7008 (Novo Nordisk)
3.4.3 Liprotamase (Eli Lilly)
3.4.4 IDegLira (Novo Nordisk)
3.4.5 LY2605541 (Eli Lilly / Boehringer Ingelheim)
3.4.6 LY2963016 (Eli Lilly / Boehringer Ingelheim)
3.4.7 FIAsp (Novo Nordisk)
3.4.8 Somatropin (LG Life Sciences)
3.4.9 Natpara (NPS Pharmaceuticals)
3.4.10 Recombinant von Willebrand Factor (Baxter)
3.4.11 IB1001 (Inspiration Biopharmaceuticals)
3.4.12 NN7088 (Novo Nordisk)
3.4.13 NN7999 (Novo Nordisk)
3.4.14 Recombinant Factor VIII Fc (Biogen Idec)
3.4.15 Recombinant Factor IX Fc (Biogen Idec)
3.4.16 BAY 94-9027 (Bayer)
3.4.17 Human Recombinant Factor VIII (Octapharma)
3.4.18 OBI-1 (Inspiration Biopharmaceuticals)
3.4.19 BIIB017 (Biogen Idec)
3.4.20 Alferon N Injection (HemispherX Biopharma)
3.4.21 PEG-interferon Lambda (Bristol-Myers Squibb)
3.4.22 NU-100 (Nuron Biotech)
3.4.23 Multikine (CEL-SCI)
3.4.24 Talactoferrin Alpha (Agennix)
3.4.25 Desmoteplase (Lundbeck)
3.4.26 Mycobacterium Cell Wall-DNA complex (Bioniche Therapeutics)

4. Monoclonal Antibodies Submarket, 2013-2023
4.1 Monoclonal Antibodies Submarket Projections for 2013-2023
4.2 Monoclonal Antibodies Submarket: Breakdown by Segment, 2013-2023
4.2.1 Autoimmune MAbs: Leading Segment of Biologics Market in 2012
4.2.1.1 Humira and Remicade Dominate Autoimmune MAbs Segment
4.2.1.2 TNF Blockers Represent 79% of All Revenues in the Autoimmune Segment
4.2.1.3Johnson & Johnson Leads the Autoimmune Segment with 41% Market Share
4.2.1.4 The Autoimmune MAbs Pipeline
4.2.1.5 Asthma and Lupus Next Behind RA as R&D Focus for Autoimmune MAbs
4.2.1.6 Competition for the Autoimmune MAbs
4.2.1.7 Drivers and Restraints for Autoimmune MAbs, 2013
4.2.1.8 Market Forecast for Autoimmune MAbs Segment, 2013-2023
4.2.2 Oncology MAbs: Focus for Next-Generation Antibody Innovation
4.2.2.1 Roche's Three Major Products Dominate the Segment
4.2.2.2 Perjeta and Kadcyla Will Cement the Importance of HER2 as Key Molecular Target
4.2.2.3 Eight Approved MAbs Target Haematological Cancers
4.2.2.4 Bristol-Myers Squibb Rank Second in Oncology Segment
4.2.2.5 Next-Generation Formats Bolster Extensive Oncology Pipeline
4.2.2.6 Solid Tumours are the Major Challenge for Oncology MAbs
4.2.2.7 Drivers and Restraints for Oncology MAbs, 2013
4.2.2.8 Market Forecast for Oncology MAbs Segment, 2013-2023
4.2.3 Other Therapeutic Areas MAbs: New Breakthroughs to Come?
4.2.3.1 Lucentis Continues to Dominate this Segment
4.2.3.2 Pipeline Targets Several New Therapeutic Areas
4.2.3.3 Anti-PCSK9 MAbs to Combine with Statins?
4.2.3.4 After Bapineuzumab: New Hope for Alzheimer's MAbs
4.2.3.5 Building on Lucentis: MAbs for Ophthalmic Indications
4.2.3.6 Anti-Infective MAbs: The New Antibiotics?
4.2.3.7 Drivers and Restraints for Other Therapeutic Areas MAbs, 2013
4.2.3.8 Market Forecast for Other Therapeutic Areas MAbs Segment, 2013-2023
4.3 Leading Products in the MAbs Submarket, 2013-2023
4.3.1 Changing Market Shares, 2013-2023
4.3.2 Humira (AbbVie), 2013-2023
4.3.2.1 Approved for Ulcerative Colitis, but will Oral RA Treatments Threaten Humira?
4.3.2.2 Market Forecast for Humira, 2013-2023
4.3.3 Remicade (Johnson & Johnson), 2013-2023
4.3.3.1 Can Remicade Survive the Biosimilar Challenge from Korea?
4.3.3.2 Market Forecast for Remicade, 2013-2023
4.3.4 Rituxan (Roche), 2013-2023
4.3.4.1 Battle for the CD20 Market: Rituxan vs The Rest
4.3.4.2 Market Forecast for Rituxan, 2013-2023
4.3.5 Herceptin (Roche), 2013-2023
4.3.5.1 The First Major PLM Strategy in the MAb Submarket: Herceptin, Perjeta and Kadcyla
4.3.5.2 Market Forecast for Herceptin, 2013-2023
4.3.6 Avastin (Roche), 2013-2023
4.3.6.1 Is Avastin Reaching its Limits?
4.3.6.2 Market Forecast for Avastin, 2013-2023
4.3.7 Other MAb Products, 2013-2023
4.3.7.1 Forecast for Other MAb Products, 2013-2023
4.4 Leading Products in Development in the MAbs Submarket, 2013
4.4.1 CNTO-136 (Johnson & Johnson)
4.4.2 Daclizumab (AbbVie/Biogen Idec)
4.4.3 Epratuzumab (UCB/ Immunomedics)
4.4.4 Ocrelizumab (Biogen Idec/ Roche)
4.4.5 Sarilumab (Sanofi)
4.4.6 Secukinumab (Novartis)
4.4.7 Tabalumab (Eli Lilly)
4.4.8 Ixekizumab (Eli Lilly)
4.4.9 Tanezumab (Pfizer)
4.4.10 Mepolizumab (GlaxoSmithKline)
4.4.11 Reslizumab (Cephalon)
4.4.12 Lebrikiuzmab (Genentech)
4.4.13 Tildrakizumab (Merck)
4.4.14 ch14.18 (United Therapeutics)
4.4.15 Inotuzumab Ozogamicin (Pfizer)
4.4.16 Elotuzumab (Bristol-Myers Squibb)
4.4.17 Farletuzumab (Eisai)
4.4.18 Ganitumab (Amgen)
4.4.19 MABp1 (Xbiotech)
4.4.20 GA101 (Roche)
4.4.21 Mogamalizumab (Kyowa Hakko Kirin)
4.4.22 Necitumumab (Eli Lilly)
4.4.23 Nivolumab (Bristol-Myers Squibb)
4.4.24 Onartuzumab (Roche)
4.4.25 Ramucirumab (Eli Lilly)
4.4.26 Girentuximab (Wilex)
4.4.27 AMG145 (Amgen)
4.4.28 SAR 236553 (Sanofi/ Regeneron)
4.4.29 Gevokizumab (XOMA)
4.4.30 Teplizumab (MacroGenics)
4.4.31 Anthraximmune Globulin (Cangene)
4.4.32 Actoxumab (Merck)
4.4.33 Romosozumab (Amgen)
4.4.34 Solanezumab (Eli Lilly)

5. Fusion Proteins Submarket, 2013-2023
5.1 Fusion Proteins Submarket Projections for 2013-2023
5.2 Leading Products in the Fusion Proteins Submarket, 2013-2023
5.2.1 New Approvals to Drive Submarket Growth to 2023
5.2.2 Enbrel (Amgen): Leading Fusion Protein, 2013
5.2.2.1 Biosimilar Enbrel Competitors on Hold?
5.2.2.2 Market Forecast for Enbrel, 2013-2023
5.2.2.3 Can Orencia Differentiate Itself in the RA Market?
5.2.3 Eylea (Regeneron): Breaking Into the AMD Market in 2012
5.2.3.1 Scope for Expansion with Eylea
5.2.3.2 Market Forecast for Eylea, 2013-2023
5.2.4 Other Fusion Proteins, 2013-2023
5.3 Leading Products in Development in the Fusion Proteins Submarket, 2013
5.3.1 Albiglutide (GlaxoSmithKline)
5.3.2 Dulaglutide (Eli Lilly)
5.3.2.1 Could the Fifth in Class Become the Best in Class?
5.3.3 Atacicept (Merck KGaA/ZymoGenetics)
5.3.4 AMG 386 (Amgen)

6. Cellular and Regenerative Medicines Submarket, 2013-2023
6.1 Cellular and Regenerative Medicines Submarket Projections for 2013-2023
6.2 Cellular and Regenerative Medicines Submarket: Breakdown by Segment, 2013-2023
6.2.1 Tissue Engineered Products: Prospects Beyond Wound Repair?
6.2.1.1 Apligraf Leads the Tissue Engineered Products Segment in 2013
6.2.1.2 Apligraf Competes with Dermagraft in Diabetic Foot Ulcers Therapeutic Area
6.2.1.3 Other Potential Applications for Tissue Engineering
6.2.1.4 Drivers and Restraints for the Tissue Engineered Products Segment, 2013
6.2.1.5 Market Forecast for Tissue Engineered Products Segment, 2013
6.2.2 Cellular Therapies Segment, 2013-2023
6.2.2.1 Approvals in Canada and South Korea Bolster Stem Cell Field
6.2.2.2 The Big Stem Cell Breakthrough I: The New Wave of MSC Treatments
6.2.2.3 The Big Stem Cell Breakthrough 2: Regenerating Organs
6.2.2.4 Chondrocytes for Cartilage Repair
6.2.2.5 Drivers and Restraints for Cellular Therapies, 2013
6.2.2.6 Market Forecast for Cellular Therapies, 2013-2023
6.2.3 Gene Therapy: Has the Time Come at Last for This Technology?
6.2.3.1 Existing Gene Therapy Products: Asian Approvals
6.2.3.2 Glybera Brings Gene Therapy to Europe
6.2.3.3 Significant Pipeline for Gene Therapies
6.2.3.4 Drivers and Restraints for Gene Therapy, 2013
6.2.3.5 Market Forecast for Gene Therapy, 2013-2023
6.3 Leading Products in Development in the Cellular and Regenerative Medicines Submarket, 2013
6.3.1 CAIS (Depuy Mitek)
6.3.2 Neocart (Histogenics Corporation)
6.3.3 Ixmyelocel-T (Aastrom Biosciences)
6.3.4 "Off-the-shelf" Mesenchymal Precursors (Mesoblast)
6.3.4.1 Gamida Cell Competing for this Market Opportunity
6.3.5 Prochymal (Osiris Therapeutics)
6.3.6 Auto-CD34+ Cells (Baxter)
6.3.6.1 NeoStem vs Baxter
6.3.7 Cx601 (Tigenix)
6.3.8 Talminogene Laherparepvec (Amgen)
6.3.9 Generx (Cardium Therapeutics)

7. Leading National Markets for Biological Drugs, 2013-2023
7.1 The US Remained the Largest Market in 2012
7.2 Overview of Market Change, 2013-2023
7.3 Breakdown by Region, 2013-2023
7.3.1 US, 2013-2023
7.3.1.1 US Health Spending Nears $3 Trillion
7.3.1.2 Value-Based Pricing in the US
7.3.1.3 US Regulation of Biologics
7.3.1.4 Biologics Price Competition and Innovation Act
7.3.1.5 Market Forecast for the US, 2013-2023
7.3.2 EU5, 2013-2023
7.3.2.1 European Leadership on Biosimilars
7.3.2.2 Other Biosimilar Regulations
7.3.2.3 Market Forecast for EU5, 2013-2023
7.3.2.4 Breakdown of the EU5, 2013-2023
7.3.3 Japan, 2013-2023
7.3.3.1 Sandoz and JCR Pioneering Japanese Biosimilars
7.3.3.2 Market Forecast for Japan, 2013-2023
7.3.4 BRIC Nations, 2013-2023
7.3.4.1 Market Forecast for the BRIC Nations, 2013-2023
7.3.4.2 Brazil: Government to Take the Lead in Biologics Manufacture?
7.3.4.3 Russia: Targeting Domestic Biomanufacturing Capacity
7.3.4.4 India: Will the Generics Hub Become the Biosimilars Leader?
7.3.4.5 China: The Major Market Opportunity
7.3.4.6 Breakdown of the BRIC Nations, 2013-2023

8. Qualitative Industry Analysis: Drivers and Restraints, 2013
8.1 Strengths: An Established and Successful Market
8.2 Weaknesses: Has the Advance of Biopharmaceuticals Reached its Limits?
8.3 Opportunities: Time for a New Phase in the Biologics Revolution
8.4 Threats: Where Will the Innovations Needed to Keep the Market Moving Come From?
8.5 Social Factors: How Much Do Physicians and Patients Want the New Biologics?
8.6 Technological Developments: Crucial to the Market
8.7 Economic Pressures: A Constant Theme in the Biologics Market
8.8 Political Issues: Governments Shaping the Regulatory Future of the Market

9. Research Interviews
9.1 Overview of the Biotech Industry in 2013: Interview with Ronald A. Rader, President of Biotechnology Information Institute
9.1.1 Steady Growth, but a Dearth of New Blockbusters
9.1.2 The Price of Biological Drugs
9.1.3 Biosimilars to Outnumber Innovator Products
9.1.4 'Differentiated Biologics': Biosimilars vs Bio-Betters
9.1.5 Changing of the Guard: Can New Classes of Biopharmaceuticals Transform the Market?
9.1.6 Big Pharma and the Biotechs
9.1.7 Bundled Payments and Bulked-up Portfolios, and Other Reasons Why Every Major Player Will Get Involved in Biosimilars
9.1.8 Modular Bioprocessing: The Next Revolution?
9.2 Next-Generation MAbs: Interview with Dr Janice Reichert
9.2.1 On Antibody-Drug Conjugates
9.2.2 On Engineered Improvements to Antibodies
9.2.3 On the Current Scientific Understanding of Antibody Functions
9.2.4 On Bispecific Antibodies
9.2.5 On Antibody Fragments and Market Pricing
9.2.6 On the Overall Prospects for Next-Generation Antibodies
9.3 MAb vs. Fusion Protein in the AMD Market: Interview with Dr Michael Stewart, Mayo Clinic
9.3.1 The Impact of Eylea, 2011-2012
9.3.2 The Comparative Dosing Schedules of Eylea and Lucentis
9.3.3 Patient Transitioning to Eylea: Salvage Switching
9.3.4 Avastin After the CATT Study
9.3.5 Prospects for Eylea in Other Indications and Combinations
9.3.6 Future Possibilities in Wet AMD Treatment
9.4 A Revolution in Regenerative Medicine? Interview with Dr Alan Trounson, President, California Institute for Regenerative Medicine (CIRM)
9.4.1 Current Stem Cell Clinical Trials
9.4.2 Big Pharma Investment in Stem Cells
9.4.3 Mesenchymal Cells in Clinical Trials
9.4.4 On Definitions of Cell Types and Regulatory Pathways
9.4.5 The Prospects for Stem Cell Cures

10. Conclusions
10.1 The Biologics Market Will Grow in Importance for the Pharmaceuticals Industry
10.2 MAbs and Protein Therapeutics Will Continue to Be the Dominant Submarkets
10.3 Biosimilars Will Transform the Market
10.4 Cost will Remain the Main Challenge

List of Tables
Table 2.1 World Biological Drugs Market: Total Revenues ($m), AGR (%), CAGR (%), 2012-2017
Table 2.2 World Biological Drugs Market: Total Revenues ($m), AGR (%), CAGR (%), 2018-2023
Table 2.3 Comparative Biological Molecule Sizes
Table 2.4 Top 10 Biological Drugs: Revenues ($m), Market Share (%), 2012
Table 2.5 Top 10 Drugs in the Global Pharmaceutical Market: Revenues ($m), 2012
Table 2.6 Key Therapeutic Areas in the Biologics Market: Revenues ($m), Market Share (%), 2012
Table 2.7 Leading Companies in the Biologics Market: Revenues ($m), Market Share (%), 2012
Table 2.8 Breakdown by Submarket: Revenues ($m), Market Share (%), 2012
Table 2.9 Breakdown by Submarket: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2012-2017
Table 2.10 Breakdown by Submarket: Revenues ($m), Market Share (%), 2017
Table 2.11 Breakdown by Submarket: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2018-2023
Table 2.12 Breakdown by Submarket: Revenues ($m), Market Share (%), 2023
Table 2.13 Regions of an Antibody
Table 2.14 Natural Antibody Mechanisms of Action
Table 2.15 Potency and Source of Stem Cells
Table 3.1 Protein Therapeutics Submarket: Total Revenues ($m), AGR (%), CAGR (%), 2012-2017
Table 3.2 Protein Therapeutics Submarket: Total Revenues ($m), AGR (%), CAGR (%), 2018-2023
Table 3.3 Protein Therapeutics Submarket Breakdown by Segment: Revenues ($m), Submarket Share (%), 2012
Table 3.4 Protein Therapeutics Submarket Breakdown by Segment: Revenues ($m), AGR (%), CAGR (%) Submarket Share (%), 2012-2017
Table 3.5 Protein Therapeutics Submarket Breakdown by Segment: Revenues ($m), Submarket Share (%), 2017
Table 3.6 Protein Therapeutics Submarket Breakdown by Segment: Revenues ($m), AGR (%), CAGR (%), Submarket Share (%), 2018-2023
Table 3.7 Protein Therapeutics Submarket Breakdown by Segment: Revenues ($m), Submarket Share (%), 2023
Table 3.8 EU and US Patent Expiry Dates for Leading Insulins
Table 3.9 Types of Insulin Product, 2013
Table 3.10 Insulins Pipeline: Selected Products, 2013
Table 3.11 Classes of Diabetes Treatments, 2013
Table 3.12 Insulins Segment: Revenues ($m), AGR (%), CAGR (%), 2012-2017
Table 3.13 Insulins Segment: Revenues ($m), AGR (%), CAGR (%), 2018-2023
Table 3.14 EU and US Patent Expiry Dates for Leading Erythropoietins
Table 3.15 Other Recombinant Hormones Pipeline: Selected Products, 2013
Table 3.16 Other Recombinant Hormones Segment: Revenues ($m), AGR (%), CAGR (%), 2012-2017
Table 3.17 Other Recombinant Hormones Segment: Revenues ($m), AGR (%), CAGR (%), 2018-2023
Table 3.18 Selected Coagulating Factors Significant in Segment R&D, 2013
Table 3.19 Plasma and Recombinant Coagulating Factors Pipeline: Selected Products, 2013
Table 3.20 Plasma and Recombinant Coagulating Factors Segment: Revenues ($m), AGR (%), CAGR (%), 2012-2017
Table 3.21 Plasma and Recombinant Coagulating Factors Segment: Revenues ($m), AGR (%), CAGR (%), 2018-2023
Table 3.22 Leading Interferon Products: Revenues ($m), Market Share (%), 2012
Table 3.23 EU and US Patent Expiry Dates for Leading Interferons
Table 3.24 Interferons Pipeline: Selected Products, 2013
Table 3.25 Interferons Segment: Revenues ($m), AGR (%), CAGR (%), 2012-2017
Table 3.26 Interferons Segment: Revenues ($m), AGR (%), CAGR (%), 2018-2023
Table 3.27 Other Protein Therapeutics Pipeline: Selected Products, 2013
Table 3.28 Other Protein Therapeutics Segment: Revenues ($m), AGR (%), CAGR (%), 2012-2017
Table 3.29 Other Protein Therapeutics Segment: Revenues ($m), AGR (%), CAGR (%), 2018-2023
Table 3.30 Leading Protein Therapeutic Products: Revenues ($m), Submarket Share (%), 2012
Table 3.31 Leading Protein Therapeutic Products: Revenues ($m), AGR (%), CAGR (%), Submarket Share (%), 2012-2017
Table 3.32 Leading Protein Therapeutic Products: Revenues ($m), Market Share (%), 2017
Table 3.33 Leading Protein Therapeutic Products: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2018-2023
Table 3.34 Leading Protein Therapeutic Products: Revenues ($m), Market Share (%), 2023
Table 3.35 Lantus: Revenues ($m), AGR (%), CAGR (%), 2012-2017
Table 3.36 Lantus: Revenues ($m), AGR (%), CAGR (%), 2018-2023
Table 3.37 Neulasta/Neupogen: Revenues ($m), AGR (%), CAGR (%), 2012-2017
Table 3.38 Neulasta/Neupogen: Revenues ($m), AGR (%), CAGR (%), 2018-2023
Table 3.39 Epogen: Revenues ($m), AGR (%), CAGR (%), 2012-2017
Table 3.40 Epogen: Revenues ($m), AGR (%), CAGR (%), 2018-2023
Table 3.41 Avonex: Revenues ($m), AGR (%), CAGR (%), 2012-2017
Table 3.42 Avonex: Revenues ($m), AGR (%), CAGR (%), 2018-2023
Table 3.43 NovoRapid: Revenues ($m), AGR (%), CAGR (%), 2012-2017
Table 3.44 NovoRapid: Revenues ($m), AGR (%), CAGR (%), 2018-2023
Table 3.45 Other Products: Revenues ($m), AGR (%), CAGR (%), 2012-2017
Table 3.46 Other Products: Revenues ($m), AGR (%), CAGR (%), 2018-2023
Table 3.47 Protein Therapeutics Late-Stage Pipeline, Selected Products, 2013
Table 4.1 Monoclonal Antibodies Submarket: Total Revenues ($m), AGR (%), CAGR (%), 2012-2017
Table 4.2 Monoclonal Antibodies Submarket: Total Revenues ($m), AGR (%), CAGR (%), 2018-2023
Table 4.3 Monoclonal Antibodies Submarket Breakdown by Segment: Revenues ($m), Market Share (%), 2012
Table 4.4 Monoclonal Antibodies Submarket Breakdown by Segment: Revenues ($m), AGR (%), CAGR (%) Market Share (%), 2012-2017
Table 4.5 Monoclonal Antibodies Submarket Breakdown by Segment: Revenues ($m), Market Share (%), 2017
Table 4.6 Monoclonal Antibodies Submarket Breakdown by Segment: Revenues ($m), AGR (%), CAGR (%) Market Share (%), 2018-2023
Table 4.7 Monoclonal Antibodies Submarket Breakdown by Segment: Revenues ($m), Market Share (%), 2023
Table 4.8 Leading Products in Autoimmune MAbs Segment, Revenues ($m), Share of Segment (%), 2012
Table 4.9 Main Molecular Targets in Autoimmune Segment: Revenues ($m), Market Share (%), 2012
Table 4.10 Level of Antibody Humanisation in Autoimmune Segment: Revenues ($m), Market Share (%), 2012
Table 4.11 Leading Companies in Autoimmune Segment: Revenues ($m), Market Share (%), 2012
Table 4.12 Autoimmune MAbs Pipeline: Selected Products, 2013
Table 4.13 RA MAbs Pipeline: Selected Products, 2013
Table 4.14 Asthma MAbs Pipeline: Selected Products, 2013
Table 4.15 Lupus MAbs Pipeline: Selected Products, 2013
Table 4.16 MS MAbs Pipeline: Selected Products, 2013
Table 4.17 Psoriasis MAbs Pipeline: Selected Products, 2013
Table 4.18 Other Autoimmune MAbs Pipeline: Selected Products, 2013
Table 4.19 Autoimmune MAbs Segment: Revenues ($m), AGR (%), CAGR (%), 2012-2017
Table 4.20 Autoimmune MAbs Segment: Revenues ($m), AGR (%), CAGR (%), 2018-2023
Table 4.21 Leading Products in Oncology MAbs Segment, Revenues ($m), Share of Segment (%), 2012
Table 4.22 Main Molecular Targets in Oncology Segment: Revenues ($m), Market Share (%), 2012
Table 4.23 Leading Companies in Oncology Segment: Revenues ($m), Market Share (%), 2012
Table 4.24 Oncology MAbs Pipeline: Selected Products, 2013
Table 4.25 Oncology MAbs Segment: Revenues ($m), AGR (%), CAGR (%), 2012-2017
Table 4.26 Oncology MAbs Segment: Revenues ($m), AGR (%), CAGR (%), 2018-2023
Table 4.27 Leading Products in Other Therapeutic Areas MAbs Segment, Revenues ($m), Share of Segment (%), 2012
Table 4.28 Other Therapeutic Areas MAbs Pipeline: Selected Products, 2013
Table 4.29 Cardiovascular MAbs Pipeline: Selected Products, 2013
Table 4.30 Alzheimer's Disease MAbs Pipeline: Selected Products, 2013
Table 4.31 Ophthalmic MAbs Pipeline: Selected Products, 2013
Table 4.32 Anti-Infectives MAbs Pipeline: Selected Products, 2013
Table 4.33 Other Therapeutic Areas MAbs Segment: Revenues ($m), AGR (%), CAGR (%), 2012-2017
Table 4.34 Other Therapeutic Areas MAbs Segment: Revenues ($m), AGR (%), CAGR (%), 2018-2023
Table 4.35 Leading MAbs: Revenues ($m), Market Share (%), 2012
Table 4.36 Leading MAbs: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2012-2017
Table 4.37 Leading MAbs: Revenues ($m), Market Share (%), 2017
Table 4.38 Leading MAbs: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2018-2023
Table 4.39 Leading MAbs: Revenues ($m), Market Share (%), 2023
Table 4.40 Humira: Revenues ($m), AGR (%), CAGR (%), Submarket Share (%), 2012-2017
Table 4.41 Humira: Revenues ($m), AGR (%), CAGR (%), Submarket Share (%), 2018-2023
Table 4.42 Remicade: Revenues ($m), AGR (%), CAGR (%), Submarket Share (%), 2012-2017
Table 4.43 Remicade: Revenues ($m), AGR (%), CAGR (%), Submarket Share (%), 2018-2023
Table 4.44 Rituxan: Revenues ($m), AGR (%), CAGR (%), Submarket Share (%), 2012-2017
Table 4.45 Rituxan: Revenues ($m), AGR (%), CAGR (%), Submarket Share (%), 2018-2023
Table 4.46 Herceptin: Revenues ($m), AGR (%), CAGR (%), Submarket Share (%), 2012-2017
Table 4.47 Herceptin: Revenues ($m), AGR (%), CAGR (%), Submarket Share (%), 2018-2023
Table 4.48 Avastin: Revenues ($m), AGR (%), CAGR (%), Submarket Share (%), 2012-2017
Table 4.49 Avastin: Revenues ($m), AGR (%), CAGR (%), Submarket Share (%), 2018-2023
Table 4.50 Other MAb Products: Revenues ($m), AGR (%), CAGR (%), Submarket Share (%), 2012-2017
Table 4.51 Other MAb Products: Revenues ($m), AGR (%), CAGR (%), Submarket Share (%), 2018-2023
Table 4.52 Selected Late-Stage MAbs Pipeline, 2013
Table 5.1 Fusion Proteins Submarket: Total Revenues ($m), AGR (%), CAGR (%), 2012-2017
Table 5.2 Fusion Proteins Submarket: Total Revenues ($m), AGR (%), CAGR (%), 2018-2023
Table 5.3 Approved Fusion Proteins, 2013
Table 5.4 Leading Products in Fusion Proteins Segment: Revenues ($m), Market Share (%), 2012
Table 5.5 Fusion Proteins Submarket Leading Products: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2012-2017
Table 5.6 Leading Products in Fusion Proteins Segment: Revenues ($m), Market Share (%), 2017
Table 5.7 Fusion Proteins Submarket Leading Products: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2018-2023
Table 5.8 Leading Products in Fusion Proteins Segment: Revenues ($m), Market Share (%), 2023
Table 5.9 Enbrel: Revenues ($m), AGR (%), CAGR (%), Submarket Share (%), 2012-2017
Table 5.10 Enbrel: Revenues ($m), AGR (%), CAGR (%), Submarket Share (%), 2018-2023
Table 5.11 Orencia: Revenues ($m), AGR (%), CAGR (%), Submarket Share (%), 2012-2017
Table 5.12 Orencia: Revenues ($m), AGR (%), CAGR (%), Submarket Share (%), 2018-2023
Table 5.13 Eylea: Revenues ($m), AGR (%), CAGR (%), Submarket Share (%), 2012-2017
Table 5.14 Eylea: Revenues ($m), AGR (%), CAGR (%), Submarket Share (%), 2018-2023
Table 5.15 Other Fusion Protein Products: Revenues ($m), AGR (%), CAGR (%), Submarket Share (%), 2012-2017
Table 5.16 Other Fusion Protein Products: Revenues ($m), AGR (%), CAGR (%), Submarket Share (%), 2018-2023
Table 5.17 Fusion Proteins Pipeline: Selected Products, 2013
Table 6.1 Cellular and Regenerative Medicines Submarket: Total Revenues ($m), AGR (%), CAGR (%), 2012-2017
Table 6.2 Cellular and Regenerative Medicines Submarket: Total Revenues ($m), AGR (%), CAGR (%), 2018-2023
Table 6.3 Cellular and Regenerative Medicines Submarket Breakdown by Segment: Revenues ($m), Market Share (%), 2012
Table 6.4 Cellular and Regenerative Medicines Submarket Breakdown by Segment: Revenues ($m), AGR (%), CAGR (%) Market Share (%), 2012-2017
Table 6.5 Cellular and Regenerative Medicines Submarket Breakdown by Segment: Revenues ($m), Market Share (%), 2017
Table 6.6 Cellular and Regenerative Medicines Submarket Breakdown by Segment: Revenues ($m), AGR (%), CAGR (%) Market Share (%), 2018-2023
Table 6.7 Cellular and Regenerative Medicines Submarket Breakdown by Segment: Revenues ($m), Market Share (%), 2023
Table 6.8 Tissue Engineered Products Pipeline: Selected Products, 2013
Table 6.9 Tissue Engineered Products Segment: Revenues ($m), AGR (%), CAGR (%), 2012-2017
Table 6.10 Tissue Engineered Products Segment: Revenues ($m), AGR (%), CAGR (%), 2018-2023
Table 6.11 Cellular Therapies Pipeline: Selected Products, 2013
Table 6.12 Cellular Therapies Segment: Revenues ($m), AGR (%), CAGR (%), 2012-2017
Table 6.13 Cellular Therapies Segment: Revenues ($m), AGR (%), CAGR (%), 2018-2023
Table 6.14 Gene Therapy Pipeline: Selected Products, 2013
Table 6.15 Gene Therapy Segment: Revenues ($m), AGR (%), CAGR (%), 2012-2017
Table 6.16 Gene Therapy Segment: Revenues ($m), AGR (%), CAGR (%), 2018-2023
Table 6.17 Cellular and Other Regenerative Medicines Submarket: Selected Late-Stage Pipeline, 2013
Table 7.1 Regional Breakdown of the Biological Drugs Market, Revenues ($m), Market Shares (%), 2012
Table 7.2 Regional Breakdown of the Biological Drugs Market: Revenues ($m), AGR (%), CAGR (%), Market Shares (%), 2012-2017
Table 7.3 Regional Breakdown of the Biological Drugs Market, Revenues ($m), Market Shares (%) 2017
Table 7.4 Regional Breakdown of the Biological Drugs Market: Revenues ($m), AGR (%), CAGR (%), Market Shares (%), 2018-2023
Table 7.5 Regional Breakdown of the Biological Drugs Market, Revenues ($m), Market Shares (%), 2023
Table 7.6 US: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2012-2017
Table 7.7 US: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2018-2023
Table 7.8 EU5: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2012-2017
Table 7.9 EU5: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2018-2023
Table 7.10 National Breakdown of the EU5, Revenues ($m), Share of Market (%), 2012
Table 7.11 National Breakdown of the EU5, Revenues ($m), AGR (%), CAGR (%), Share of Market (%), 2012-2017
Table 7.12 National Breakdown of the EU5, Revenues ($m), Share of Market (%), 2017
Table 7.13 National Breakdown of the EU5, Revenues ($m), AGR (%), CAGR (%), Share of Market (%), 2018-2023
Table 7.14 National Breakdown of the EU5, Revenues ($m), Share of Market (%) 2023
Table 7.15 Japan: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2012-2017
Table 7.16 Japan: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2018-2023
Table 7.17 BRIC Nations: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2012-2017
Table 7.18 BRIC Nations: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2018-2023
Table 7.19 National Breakdown of the BRIC Nations, Revenues ($m), Share of Market (%) 2012
Table 7.20 National Breakdown of the BRIC Nations, Revenues ($m), AGR (%), CAGR (%), Share of Market (%), 2012-2017
Table 7.21 National Breakdown of the BRIC Nations, Revenues ($m), Share of Market (%), 2017
Table 7.22 National Breakdown of the BRIC Nations, Revenues ($m), AGR (%), CAGR (%), Share of Market (%), 2018-2023
Table 7.23 National Breakdown of the BRIC Nations, Revenues ($m), Share of Market (%), 2023
Table 8.1 World Biologics Market: Strengths and Weaknesses, 2013
Table 8.2 World Biologics Market: Opportunities and Threats, 2013
Table 8.3 World Biologics Market: STEP Analysis, 2013-2023

List of Figures
Figure 2.1 World Biological Drugs Market: Total Revenues ($m), 2012-2023
Figure 2.2 Comparative Biological Molecule Sizes
Figure 2.3 Biologics Market as Sector Within the Global Pharmaceuticals Market: Revenues ($bn), Market Share (%), 2012
Figure 2.4 Top 10 Biological Drugs: Revenues ($m), Market Share (%), 2012
Figure 2.5 Top 10 Drugs in the Global Pharmaceutical Market: Revenues ($m), 2012
Figure 2.6 Biosimilars as Segment of the Overall Biologics Market: Revenues ($m), Market Share (%), 2012, 2017, 2023
Figure 2.7 Key Therapeutic Areas in the Biologics Market: Revenues ($m), Market Share (%), 2012
Figure 2.8 Key Therapeutic Areas in the Biologics Market, Compared to Overall Pharmaceutical Market: Market Share (%), 2012
Figure 2.9 Breakdown by Submarket: Revenues ($m), Market Share (%), 2012
Figure 2.10 Breakdown by Submarket: Revenues ($m), Market Share (%), 2017
Figure 2.11 Breakdown by Submarket: Revenues ($m), Market Share (%), 2023
Figure 2.12 Breakdown by Submarket: Revenues ($m), 2012-2023
Figure 2.13 Breakdown by Submarket: Revenues ($m), 2012, 2017, 2023
Figure 3.1 Protein Therapeutics Submarket: Total Revenues ($m), 2012-2023
Figure 3.2 Protein Therapeutics Submarket Breakdown by Segment: Revenues ($m), Submarket Share (%), 2012
Figure 3.3 Protein Therapeutics Submarket Breakdown by Segment: Revenues ($m), Submarket Share (%), 2017
Figure 3.4 Protein Therapeutics Submarket Breakdown by Segment: Revenues ($m), Submarket Share (%), 2023
Figure 3.5 Protein Therapeutics Submarket Breakdown by Segment: Revenues ($m), 2012-2023
Figure 3.6 Protein Therapeutics Submarket Breakdown by Segment: Revenues ($m), 2012, 2017, 2023
Figure 3.7 Drivers and Restraints in the Insulins Segment, 2013
Figure 3.8 Insulins Segment: Revenues ($m), 2012-2023
Figure 3.9 Drivers and Restraints in the Other Recombinant Hormones Segment, 2013
Figure 3.10 Other Recombinant Hormones Segment: Revenues ($m), 2012-2023
Figure 3.11 Drivers and Restraints in the Plasma and Recombinant Coagulating Factors Segment, 2013
Figure 3.12 Plasma and Recombinant Coagulating Factors Segment: Revenues ($m), 2012-2023
Figure 3.13 Leading Interferon Products: Revenues ($m), Market Share (%), 2012
Figure 3.14 Drivers and Restraints for the Interferons Segment, 2013
Figure 3.15 Interferons Segment: Revenues ($m), 2012-2023
Figure 3.16 Other Protein Therapeutics Segment: Revenues ($m), 2012-2023
Figure 3.17 Leading Protein Therapeutic Products: Revenues ($m), Submarket Share (%), 2012
Figure 3.18 Leading Protein Therapeutic Products: Revenues ($m), Market Share (%), 2017
Figure 3.19 Leading Protein Therapeutic Products: Revenues ($m), Market Share (%), 2023
Figure 3.20 Leading Protein Therapeutic Products: Revenues ($m), 2012-2023
Figure 3.21 Leading Protein Therapeutic Products: Revenues ($m), 2012, 2017, 2023
Figure 3.22 Drivers and Restraints for Lantus, 2013
Figure 3.23 Lantus: Revenues ($m), 2012-2023
Figure 3.24 Drivers and Restraints for Neulasta/Neupogen, 2013
Figure 3.25 Neulasta/Neupogen: Revenues ($m), 2012-2023
Figure 3.26 Drivers and Restraints for Epogen, 2013
Figure 3.27 Epogen: Revenues ($m), 2012-2023
Figure 3.28 Drivers and Restraints for Avonex, 2013
Figure 3.29 Avonex: Revenues ($m), 2012-2023
Figure 3.30 Drivers and Restraints for NovoRapid, 2013
Figure 3.31 NovoRapid: Revenues ($m), 2012-2023
Figure 3.32 Other Products: Revenues ($m), 2012-2023
Figure 4.1 Monoclonal Antibodies Submarket: Total Revenues ($m), 2012-2023
Figure 4.2 Monoclonal Antibodies Submarket Breakdown by Segment: Revenues ($m), Market Share (%), 2012
Figure 4.3 Monoclonal Antibodies Submarket Breakdown by Segment: Revenues ($m), Market Share (%), 2017
Figure 4.4 Monoclonal Antibodies Submarket Breakdown by Segment: Revenues ($m), Market Share (%), 2023
Figure 4.5 Monoclonal Antibodies Submarket Breakdown by Segment: Revenues ($m), 2012-2023
Figure 4.6 Monoclonal Antibodies Submarket Breakdown by Segment: Revenues ($m), 2012, 2017, 2023
Figure 4.7 Leading Products in Autoimmune MAbs Segment, Revenues ($m), Share of Segment (%), 2012
Figure 4.8 Main Molecular Targets in Autoimmune Segment: Revenues ($m), Market Share (%), 2012
Figure 4.9 Level of Antibody Humanisation in Autoimmune Segment: Revenues ($m), Market Share (%), 2012
Figure 4.10 Leading Companies in Autoimmune Segment: Revenues ($m), Market Share (%), 2012
Figure 4.11 Drivers and Restraints for Autoimmune MAbs Segment, 2013
Figure 4.12 Autoimmune MAbs Segment: Revenues ($m), 2012-2023
Figure 4.13 Leading Products in Oncology MAbs Segment, Revenues ($m), Share of Segment (%), 2012
Figure 4.14 Main Molecular Targets in Oncology Segment: Revenues ($m), Market Share (%), 2012
Figure 4.15 Leading Companies in Oncology Segment: Revenues ($m), Market Share (%), 2012
Figure 4.16 Drivers and Restraints for Oncology MAbs Segment, 2013
Figure 4.17 Oncology MAbs Segment: Revenues ($m), 2012-2023
Figure 4.18 Leading Products in Other Therapeutic Areas MAbs Segment, Revenues ($m), Share of Segment (%), 2012
Figure 4.19 Drivers and Restraints for Other Therapeutic Areas MAbs Segment, 2013
Figure 4.20 Other Therapeutic Areas MAbs Segment: Revenues ($m), 2012-2023
Figure 4.21 Leading MAbs: Revenues ($m), Market Share (%), 2012
Figure 4.22 Leading MAbs: Revenues ($m), Market Share (%), 2017
Figure 4.23 Leading MAbs: Revenues ($m), Market Share (%), 2023
Figure 4.24 Leading MAbs: Revenues ($m), 2012-2023
Figure 4.25 Leading MAbs: Revenues ($m), 2012, 2017, 2023
Figure 4.26 Drivers and Restraints for Humira, 2013
Figure 4.27 Humira: Revenues ($m), 2012-2023
Figure 4.28 Drivers and Restraints for Remicade, 2013
Figure 4.29 Remicade: Revenues ($m), 2012-2023
Figure 4.30 Drivers and Restraints for Rituxan, 2013
Figure 4.31 Rituxan: Revenues ($m), 2012-2023
Figure 4.32 Drivers and Restraints for Herceptin, 2013
Figure 4.33 Herceptin: Revenues ($m), 2012-2023
Figure 4.34 Drivers and Restraints for Avastin, 2013
Figure 4.35 Avastin: Revenues ($m), 2012-2023
Figure 4.36 Other MAb Products: Revenues ($m), 2012-2023
Figure 5.1 Fusion Proteins Submarket: Total Revenues ($m), 2012-2023
Figure 5.2 Leading Products in Fusion Proteins Segment: Revenues ($m), Market Share (%), 2012
Figure 5.3 Leading Products in Fusion Proteins Segment: Revenues ($m), Market Share (%), 2017
Figure 5.4 Leading Products in Fusion Proteins Segment: Revenues ($m), Market Share (%), 2023
Figure 5.5 Leading Products in Fusion Proteins Segment: Revenues ($m), 2012-2023
Figure 5.6 Leading Products in Fusion Proteins Segment: Revenues ($m), 2012, 2017, 2023
Figure 5.7 Drivers and Restraints for Enbrel, 2013
Figure 5.8 Enbrel: Revenues ($m), 2012-2023
Figure 5.9 Orencia: Revenues ($m), 2012-2023
Figure 5.10 Drivers and Restraints for Eylea, 2013
Figure 5.11 Eylea: Revenues ($m), 2012-2023
Figure 5.12 Other Fusion Protein Products: Revenues ($m), 2012-2023
Figure 6.1 Cellular and Regenerative Medicines Submarket: Total Revenues ($m), 2012-2023
Figure 6.2 Cellular and Regenerative Medicines Submarket Breakdown by Segment: Revenues ($m), Market Share (%), 2012
Figure 6.3 Cellular and Regenerative Medicines Submarket Breakdown by Segment: Revenues ($m), Market Share (%), 2017
Figure 6.4 Cellular and Regenerative Medicines Submarket Breakdown by Segment: Revenues ($m), Market Share (%), 2023
Figure 6.5 Cellular and Regenerative Medicines Submarket Breakdown by Segment: Revenues ($m), 2012-2023
Figure 6.6 Cellular and Regenerative Medicines Submarket Breakdown by Segment: Revenues ($m), 2012, 2017, 2023
Figure 6.7 Tissue Engineered Products: Drivers and Restraints, 2013
Figure 6.8 Tissue Engineered Products Segment: Revenues ($m), 2012-2023
Figure 6.9 Cellular Therapies: Drivers and Restraints, 2013
Figure 6.10 Cellular Therapies Segment: Revenues ($m), 2012-2023
Figure 6.11 Gene Therapy: Drivers and Restraints, 2013
Figure 6.12 Gene Therapy Segment: Revenues ($m), 2012-2023
Figure 7.1 Regional Breakdown of the Biological Drugs Market, Revenues ($m), Market Shares (%), 2012
Figure 7.2 Regional Breakdown of the Biological Drugs Market, Revenues ($m), Market Shares (%), 2017
Figure 7.3 Regional Breakdown of the Biological Drugs Market, Revenues ($m), Market Shares (%), 2023
Figure 7.4 Regional Breakdown of the Biological Drugs Market: Revenues ($m), 2012-2023
Figure 7.5 Regional Breakdown of the Biological Drugs Market: Revenues ($m), 2012, 2017, 2023
Figure 7.6 Healthcare Spending as Share of GDP (%) for the US, France, Germany, the UK, Spain and Italy, 2010
Figure 7.7 US: Revenues ($m), 2012-2023
Figure 7.8 EU5: Revenues ($m), 2012-2023
Figure 7.9 National Breakdown of the EU5, Revenues ($m), Share of Market (%), 2012
Figure 7.10 National Breakdown of the EU5, Revenues ($m), Share of Market (%), 2017
Figure 7.11 National Breakdown of the EU5, Revenues ($m), Share of Market (%), 2023
Figure 7.12 National Breakdown of the EU5, Revenues ($m), 2012-2023
Figure 7.13 National Breakdown of the EU5, Revenues ($m), 2012, 2017, 2023
Figure 7.14 Japan: Revenues ($m), 2012-2023
Figure 7.15 BRIC Nations: Revenues ($m), 2012-2023
Figure 7.16 National Breakdown of the BRIC Nations, Revenues ($m), Share of Market (%), 2012
Figure 7.17 National Breakdown of the BRIC Nations, Revenues ($m), Share of Market (%), 2017
Figure 7.18 National Breakdown of the BRIC Nations, Revenues ($m), Share of Market (%), 2023
Figure 7.19 National Breakdown of the BRIC Nations, Revenues, 2012-2023
Figure 7.20 National Breakdown of the BRIC Nations, Revenues, 2012, 2017, 2023
Figure 10.1 World Biologics Market: Revenues ($m), 2012-2017
Figure 10.2 World Biologics Market: Revenues ($m), 2018-2023
Figure 10.3 Breakdown by Submarket: Revenues ($m), 2012-2023
Figure 10.4 Breakdown by Segment: Revenues ($m), 2012-2023

To view free sample pages of this report please click here

Companies Listed

3SBio
AbbVie
AbGenomics International
Ablynx
Actavis
Actinium Pharmaceuticals
Advanced Technologies and Regenerative Medicine
Aerovance
AET BioTech
Affimed Therapeutics
Agennix
Agensys
AgonOx
Alcon Labs (subsidiary of Novartis)
Alder Biopharmaceuticals
Alexion
Allergan
Allozyme
Altor BioScience
Altrika
Ambrx
Amgen
Apeiron Biologics
AREVA Med
Argos Therapeutics
Artaeus Therapeutics
Artisan Pharma
AryoGen
Asahi Kasei Pharma
Astellas
AstraZeneca
AVEO Oncology
Avesthagen
Avita Medicals
Baxter
Bayer
Beijing Shuanglu Medicine
BioArctic Neuroscience
BioCancell Therapeutics
Biocon
Biogen Idec
BioInvent International
Biolex
Bioniche Therapeutics
Biopartners
BioSante Pharmaceuticals
Biotest
Bioton
Biotechnology Information Institute
BioXpress Therapeutics
Boehringer Ingelheim
Bristol-Myers Squibb
BZL Biologics
California Institute for Regenerative Medicine (CIRM)
Cambridge Antibody Technology
Cangene
Catalyst Biosciences
CCL Pharmaceuticals
Cell Control
CellCoTec
Celldex
Cell Therapeutics
Celltrion
CEL-SCI
Celtic Pharma
Centocor (subsidiary of Johnson & Johnson)
Cephalon (part of Teva Pharmaceutical Industries)
Chiron
Chugai (subsidiary of Roche)
CinnaGen
Circadian Technologies
Clinimmune Labs
Co-Genesys
Compass Biotechnologies
Crucell
CSL Behring
CT Arzneimittel
CureTech
Cytheris
Cytimmune Sciences
CytoDyn
Cytograft Tissue Engineering
Cytovance Biologics
Daiichi Sankyo
Dekkun
Dendreon
Depuy Mitek
Dompé
Dong-A
Dr. Reddy's Laboratories
Duke University School of Medicine
Eisai
Elan
Eli Lilly
Elusys Therapeutics
EMA (European Medicines Agency)
Emergent BioSolutions
Endo Pharmaceuticals
Esteve
Exsulin
Facet
FDA (Food and Drug Administration, US)
Feron
Fibrocell Science
Fibrogen
Fresenius
Fujifilm Kyowa Kirin Biologics
Fuji Pharma
Functional Genetics
Galaxy Biotech
Gedeon Richter
Genentech
Genesis
GenMab
Genzyme
Getz Pharma
Gilead Sciences
GlaxoSmithKline
Glycotope
Grifols
Halozyme Therapeutics
HanAll Biopharma
Hanmi Pharmaceutical
Helix BioPharma
HemispherX Biopharma
Hexal
Histogenics
Hoechst Marion Roussel
Hospira
Hualida Biotech
Human Genome Sciences
ImClone Systems
Immunocore
ImmunoGen
Immunomedics
InnoMab PTE
Inspiration Biopharmaceuticals
ISTO Technologies
Intarcia Therapeutics
Intas Biopharmaceuticals
InterMune
InterveXion Therapeutics
Ipsen
Janssen Alzheimer Immunotherapy (subsidiary of Johnson & Johnson)
Janssen Biotech (subsidiary of Johnson & Johnson)
Johnson & Johnson
KaloBios Pharmaceuticals
Kaketsuken
Korean Food and Drug Administration
Kyowa Hakko Kirin
Labrys Biologics
LFB
LG Life Sciences
LifeCell
Life Science Pharmaceuticals
Lipoxen
Lpath
Lundbeck
Mabgene
MabVax Therapeutics
MassBiologics
Maxygen
Mayo Clinic
Medarex (subsidiary of Bristol-Myers Squibb)
Medice
MedImmune (subsidiary of AstraZeneca)
Medixion
Medtronic
Menarini
MENTRIK Biotech
Merck & Co.
Merck KGaA
Merrimack Pharmaceuticals
Merz Pharma
Michigan University
Micromet (subsidiary of Amgen)
Millennium
Minapharm Pharmaceuticals
Ministry of Health, Labour and Welfare (MHLW, Japan)
Mitsubishi Tanabe
Mochida Pharmaceutical
Morphosys
Myriad
The National Hemophilia Foundation (US)
National Institute of Allergy and Infectious Diseases (US)
National Institute for Health and Clinical Excellence (NICE, UK)
Neogenix Oncology
Neurochem
New York Blood Center
Nippon Kayaku
NovaQuest
Novo Nordisk
Novartis
NPS Pharmaceuticals
Nuron Biotech
NuVasive
Octapharma
OncoMed Pharmaceuticals
Organogenesis
Ortho Pharmaceutical Corporation (subsidiary of Johnson & Johnson)
Otsuka
Pacira Pharmaceuticals
Parexel
PDL BioPharma
Peptech
Peregrine Pharmaceuticals
Pfizer
Pharmstandard
PlantForm
Prana Biotechnology
ProChon Biotech
Progenics Pharmaceuticals
Prolor Biotech
Promedior
Prometheus Laboratories
Proteon Therapeutics
Quest Pharmatech
Quintiles Transnational
Qilu
ratiopharm
Regeneron
Reliance Life Sciences
Repligen
Rentschler Biotechnologie
rEVO Biologics (subsidiary of LFB)
Roche
Sandoz (subsidiary of Novartis)
Sanofi
Santarus
Schering-Plough (subsidiary of Merck & Co.)
SciGen (subsidiary of Bioton)
Seattle Genetics
Selexys Pharmaceuticals
Shantha Biotechnics
Shire Regenerative Medicine
Singapore Eye Research Institute (SERI)
Spectrum
Stada
Stanford University
Stratatech
Stem Cell Therapeutics
Swedish Orphan Biovitrum
Symphogen
Syntonix
TaiMed Biologics
Takeda
Targacept
Targa Therapeutics
TauRx
Tengion
Teva Pharmaceutical Industries
TG Therapeutics
Theraclone Sciences
TiGenix
Tolera Therapeutics
Toronto University
TPG-Axon Capital
TRACON Pharmaceuticals
Transkaryotic Therapies
TransTech
Tufts Center for the Study of Drug Development
UCB
UCSF
United Therapeutics
University of Colorado Cord Blood Bank
University Hospital of Tubingen
University of Tokyo
Vaccinex
Versartis
Vertex Pharmaceuticals
Vidara Therapeutics International
Viropharma
Viventia Biotechnologies
Wake Forest University Baptist Medical Center
Walter and Eliza Hall Institute
Wilex
Wockhardt
Wyeth (subsidiary of Pfizer)
Xbiotech
Xencor
XOMA
Zilip-Pharma
Zimmer
Zydus Cadila
ZymoGenetics

To view free sample pages of this report please click here

 

You have successfully subscribed. Thank you.

An internal error has occurred. Please try again later.

close